
Opinion|Videos|May 28, 2025
Clinical Insights Into Managing Heavily Pretreated HER2+ Metastatic Breast Cancer
Panelists discuss how they approach treatment beyond third-line therapy for HER2-positive (HER2+) metastatic breast cancer, considering factors such as prior therapies, residual toxicities, and patient preferences when selecting from multiple options.
Advertisement
Episodes in this series

Clinical Brief: Beyond Third-Line Therapy in HER2+ Metastatic Breast Cancer
Key Themes:
- Clinical Trial Priority: Enrollment in clinical trials is ideal for heavily pretreated patients
- Fourth-Line Options: If the HER2CLIMB regimen is used in the third line, T-DM1 becomes a preferred fourth-line option
- Personalized Selection Factors: Prior treatments, residual toxicities, and patient preferences guide therapy selection in later lines
Key Points for Physicians:
- Multiple guideline-supported options exist beyond the third line, including taxanes with trastuzumab, capecitabine with trastuzumab or lapatinib, margetuximab, and others
- Consider residual toxicities when selecting later-line therapy (eg, avoid taxanes with significant neuropathy)
- Limited clinical experience exists with sequential tyrosine kinase inhibitor (TKI) use (eg, neratinib after tucatinib)
- Novel agents in clinical trials include new antibody-drug conjugates and bispecific antibodies
Notable Insights:
- Decision-making becomes highly nuanced in later lines of therapy
- Despite multiple theoretical options, some agents such as margetuximab have limited real-world adoption
- The theoretical rationale for sequential TKI use based on specificity profiles has not been widely tested in practice
Clinical Significance:
Beyond third-line therapy for HER2+ metastatic breast cancer, treatment selection becomes increasingly individualized based on prior treatments, toxicity profiles, and patient preferences, with clinical trials offering the most promising opportunities for heavily pretreated patients.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5



































